Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 9/20 | 0.48 |
| ▸ | FPR2 | P25090 | 4/20 | 0.48 |
| ▸ | EDNRB | P24530 | 2/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGAV | P06756 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7697653 | 0.86 | ITGB3 (0.41) | FPR1FPR2ITGB3ITGAVGAA | |
| SCHEMBL4431178 | 0.86 | ITGB3 (0.41) | FPR1FPR2ITGB3ITGAVGAA | |
| SCHEMBL4436751 | 0.86 | ITGB3 (0.41) | FPR1FPR2ITGB3ITGAVGAA | |
| SCHEMBL4434014 | 0.84 | ITGB3 (0.42) | FPR1FPR2ITGB3ITGAVGAA | |
| SCHEMBL4436976 | 0.84 | ITGB3 (0.42) | FPR1FPR2ITGB3ITGAVGAA | |
| SCHEMBL4426938 | 0.84 | ITGB3 (0.41) | FPR1FPR2ITGB3ITGAVGAA | |
| SCHEMBL4428449 | 0.82 | ITGB3 (0.42) | ITGB3ITGAVGAA | |
| SCHEMBL4430045 | 0.81 | GAA (0.40) | ITGB3ITGAVGAA | |
| SCHEMBL4430042 | 0.81 | GAA (0.40) | ITGB3ITGAVGAA | |
| SCHEMBL4436896 | 0.81 | ITGB3 (0.40) | FPR1FPR2ITGB3ITGAVGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1213288-B1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC (US) | 2009-01-14 | — | — | EP | disclosed |
| US-6723711-B2 | VASCULAR CELL ADHESION MOLECULES AND FIBRONECTINS; ASTHMA, MULTIPLE SCLEROSIS, ARTHRITIS, INFLAMMATORY BOWEL DISEASE, CONTACT HYPERSENSITIVITY, CARDIAC ALLOGRAFT REJECTION AND DIABETES TREATMENT | TEXAS BIOTECHNOLOGY CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-20030199692-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2000068188-A9 | PROPANOIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORP (US) | 2002-08-29 | — | — | WO | disclosed |
| EP-1213288-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199692-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, FN1 | FPR1 40/4885FPR2 248/4885EDNRB 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.